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Lysophosphatidic acid (LPA) species in the extracellular environment induce downstream
signaling via six different G protein-coupled receptors (LPAR1–6). These signaling
cascades are essential for normal brain development and function of the nervous system.
However, in response to acute or chronic central nervous system (CNS) damage,
LPA levels increase and aberrant signaling events can counteract brain function.
Under neuro-inflammatory conditions signaling along the LPA/LPAR5 axis induces a
potentially neurotoxic microglia phenotype indicating the need for new pharmacological
intervention strategies. Therefore, we compared the effects of two novel small-molecule
LPAR5 antagonists on LPA-induced polarization parameters of the BV-2 microglia
cell line. AS2717638 is a selective piperidine-based LPAR5 antagonist (IC50 0.038
µM) while compound 3 is a diphenylpyrazole derivative with an IC50 concentration
of 0.7 µM in BV-2 cells. Both antagonists compromised cell viability, however, at
concentrations above their IC50 concentrations. Both inhibitors blunted LPA-induced
phosphorylation of STAT1 and STAT3, p65, and c-Jun and consequently reduced the
secretion of pro-inflammatory cyto-/chemokines (IL-6, TNFα, IL-1β, CXCL10, CXCL2,
and CCL5) at non-toxic concentrations. Both compounds modulated the expression
of intracellular (COX-2 and Arg1) and plasma membrane-located (CD40, CD86, and
CD206) polarization markers yet only AS2717638 attenuated the neurotoxic potential
of LPA-activated BV-2 cell-conditioned medium towards CATH.a neurons. Our findings
from the present in vitro study suggest that the two LPAR5 antagonists represent
valuable pharmacological tools to interfere with LPA-induced pro-inflammatory signaling
cascades in microglia.
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INTRODUCTION
The brain is an immune-privileged organ (Ransohoff and Brown,
2012), yet the central nervous system (CNS) is able to mount a
primary immune response since host defense mechanisms are
operative in astrocytes and microglia. Microglia are the resident
immune cells of CNS and able to detect subtle alterations of the
finely tuned micromilieu in the CNS (Ransohoff and Perry, 2009;
Ransohoff and Cardona, 2010; Garaschuk and Verkhratsky,
2019; Norris and Kipnis, 2019). Microglia cover the whole CNS
parenchyma and originate from embryonic progenitors in the
yolk sac (Ginhoux et al., 2010; Butovsky and Weiner, 2018).
These cells are unevenly distributed in the brain acquiring
different morphologies, ranging from small, round cells to those
having multiple branched processes (Hammond et al., 2018).
These cells are a self-renewing, long-lived in vivo population, not
replaced by peripheral monocytes (Ginhoux and Prinz, 2015),
with a critical role in both, the physiological and pathological
brain (Salter and Stevens, 2017; Hammond et al., 2018; Smolders
et al., 2019). In their ‘‘resting’’ state, microglia processes scan
their environment and respond to danger signals (Nimmerjahn
et al., 2005). They are equipped with a unique cluster of
transcripts encoding proteins for sensing endogenous ligands,
collectively termed the microglia sensome (Hickman et al., 2013).
Within the last years, great progress in understanding and
analyzing differences in microglia responses under pathological
conditions has been made (Colonna and Butovsky, 2017;
Wolf et al., 2017). Microglia regulate numerous aspects
of inflammation, such as regeneration, cytotoxicity, and
immunosuppression depending on their different activation
states (Du et al., 2016). During disease progression they
appear to be highly heterogeneous in terms of neurotoxic/pro-
inflammatory or neuroprotective/anti-inflammatory responses
(Tang and Le, 2016). Distinct molecular signatures and different
microglia sub-populations have been identified, revealing major
spatial, temporal and gender differences (Grabert et al.,
2016; Guneykaya et al., 2018; Masuda et al., 2019), as
well as differences associated with aging and context of
the neurodegenerative disease (Colonna and Butovsky, 2017;
Hickman et al., 2018; Song and Colonna, 2018; Mukherjee et al.,
2019). Recently, the application of powerful methodologies has
revealed unique phenotypic signatures under both physiological
and neurodegenerative settings (Tay et al., 2018; Böttcher et al.,
2019; Hammond et al., 2019; Masuda et al., 2019).
The lysophosphatidic acid (LPA) family consists of
small alkyl- or acyl-glycerophospholipids (molecular mass:
430–480 Da) that act as extracellular signaling molecules
through at least six G protein-coupled receptors (GPCRs;
Yung et al., 2014). There is a range of structurally related LPA
species present in various biological systems (Aoki, 2004). An
important aspect of LPA receptor biology is that different LPA
species may activate different LPA receptor isoforms (Kano
et al., 2008). There are two major synthetic pathways for LPA
(Yung et al., 2014). In the first pathway, phospholipids (PLs)
are converted to their corresponding lysophospholipids such as
lyso-phosphatidylcholine, -serine, or -ethanolamine. This occurs
via phosphatidylserine-specific phospholipase A1 (PS-PLA1) or
secretory phospholipase A2 (sPLA2) activity. Lysophospholipids
are then converted to LPA via head group hydrolysis by autotaxin
(ATX). In a second synthetic route, phosphatidic acid (PA),
produced from PLs through phospholipase D (PLD) activity
or from diacylglycerol (DAG) through diacylglycerol kinase
(DGK) activity, is subsequently converted to LPA by the actions
of either PLA1 or PLA2 (Aoki et al., 2008). LPA acts through
specific G protein-coupled LPA receptors (LPAR1-LPAR6)
that mediate the diverse effects of these lysophospholipids
(Yung et al., 2014).
Under physiological conditions, LPA-mediated signaling
is essential for normal neurogenesis and function of the CNS.
However, in response to injury LPA levels can increase in brain
and CSF (Tigyi et al., 1995; Savaskan et al., 2007; Ma et al.,
2010; Yung et al., 2011; Santos-Nogueira et al., 2015). Aberrant
LPA signaling contributes to multiple disease states, including
neuropathic pain, neurodegenerative, neurodevelopmental
and neuropsychiatric disorders, cardiovascular disease, bone
disorders, fibrosis, cancer, infertility, and obesity (Yung et al.,
2014). Microglia express LPA receptors and are activated by
LPA (Möller et al., 2001; Bernhart et al., 2010). In the murine
BV-2 microglia cells, LPA activates Ca2+-dependent K+ currents
resulting in membrane hyperpolarization (Schilling et al., 2002)
and induces cell migration via Ca2+-activated K+ channels
(Schilling et al., 2004). In addition, LPA controls microglial
activation and energy homeostasis (Bernhart et al., 2010),
modulates the oxidative stress response (Awada et al., 2012),
regulates the induction of chronic pain (Sun et al., 2012),
and interferes with pro-inflammatory cytokine production
(Awada et al., 2014).
LPAR5 was identified through screening approaches directed
towards the deorphanization of GPR92 (Kotarsky et al., 2006).
Signaling through the G12/13 pathway induces neurite retraction,
stress fiber formation, and receptor internalization in vitro,
while activation of Gq increases intracellular calcium levels
and induce cAMP accumulation (Lee et al., 2006). LPAR5 is
expressed in various tissues both in humans and mice (Amisten
et al., 2008; Lundequist and Boyce, 2011; Yung et al., 2014). In
the CNS, LPAR5 was found in the early embryonic forebrain,
midbrain, and hindbrain of Slc:ddY mice. This expression
pattern becomes more ubiquitous from E9.5–E12.5, showing
diffuse patterns in the developing brain and choroid plexus
revealing a role for LPAR5 in brain development (Ohuchi et al.,
2008). LPAR5 signaling contributes to nerve injury-triggered
pain (Lin et al., 2012; Ueda et al., 2013) and multiple sclerosis-
associated neuropathic pain (Tsukahara et al., 2018). Findings
that LPAR5 is activated during nerve injury (but not under
basal conditions) are consistent with the fact that LPA levels
rise significantly in response to spinal cord injury (Ma et al.,
2010; Santos-Nogueira et al., 2015). Activatedmicroglia were also
suggested to contribute to demyelination in the injured spinal
cord (Santos-Nogueira et al., 2015).
Although LPAR5 signaling was mainly studied in the context
of neuropathic pain, we could recently show that LPAR5 affects
microglia biology and induces a distinct pro-inflammatory
and migratory signature (Plastira et al., 2016, 2017). The
identification of the LPA/LPAR5 axis as a signaling pathway
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contributing to the inflammatory response of microglia might
foster deeper insights into LPA-mediated effects on the resident
immune cells of the brain. Since the binding domain of
LPAR5 represents an extracellular target, it is ideally suited
for pharmacological intervention. Accordingly, LPAR5 specific
antagonists were developed to modulate the LPA/LPAR5 axis
and study its role in development and progression of (neuro-)
inflammatory diseases (Kozian et al., 2012, 2016; Murai et al.,
2017; Kawamoto et al., 2018). In the present study, we
analyzed the potential of two structurally diverse non-lipid
LPAR5 antagonists (compound 3 and AS2717638; Kozian
et al., 2016; Murai et al., 2017) to interfere with LPA-induced
inflammatory signaling cascades in BV-2 microglia cells.
MATERIALS AND METHODS
Materials
Cell culture medium RPMI1640, fetal calf serum
(FCS), antibiotics, culture reagents, and trypsin were from
Invitrogen (Waltham, MA, USA). LPA (1-oleoyl-2-hydroxy-
sn-glycero-3-phosphate; LPA18:1) was from Sigma-Aldrich
(St. Louis, MO, USA). Antibodies against COX-2, Arginase-1
and the nonphosphorylated and phosphorylated p65-NFkB,
c-Jun, STAT1, and STAT3 were from Cell Signaling (Beverly,
MA, USA); PE-CD40, APC-CD86, PE-CD206 antibodies
and their isotype controls were from Biolegend (San Diego,
CA, USA). Monoclonal anti-mouse β-actin (clone AC-74)
was from Sigma-Aldrich (St. Louis, MO, USA). The LPAR5
inhibitors, AS2717638 [6,7-Dimethoxy-2-(5-methyl-1,2-
benzoxazol-3-yl)-4-(piperidin-1-ylcarbonyl)isoquinolin-1(2H)-
one] and compound 3 [4-((2-((1-(2,4-dichlorophenyl)-4-methyl-
5-(4-(trifluoromethyl)phenyl)-1H-spyrazol-3-yl)methoxy)-2-
methylpropanamido)methyl)benzoic acid] were synthesized
according to the published procedures (Kozian et al., 2016;
Murai et al., 2017).
For AS2717638, mass analysis was performed with an
Agilent Technologies 6230 Accurate Mass TOF LC/MS linked
to Agilent Technologies HPLC 1260 Series using a Thermo
Accuore RP-MS column (30 × 2.1 mm, 2.6 µm particle size;
Eluent A: H2O with 0.1% formic acid Eluent B: MeCN with
0.1% formic acid; Gradient: 0.00 min 95% A, 0.2 min 95%
A, 1.1 min 1% A, 2.5 min stop-time, 1.3 min post-time;
Flow rate: 0.8 ml/min; UV-detection: 220 nm, 254 nm, and
300 nm). LC-MS: Rt = 1.873 min; HRMS (ESIpos): m/z [M
+ H]+ experimentally determined = 448.1454, calculated for
C25H25N3O5 = 448.1467.
1H NMR (300 MHz, DMSO-d6) δ 7.80–7.75 (m, 2H), 7.64 (s,
1H), 7.62–7.56 (m, 2H), 6.95 (s, 1H), 3.94 (s, 3H), 3.93 (s, 3H),
3.75–3.52 (m, 2H), 3.52–3.36 (m, 2H), 2.44 (s, 3H), 1.68–1.54 (m,
4H), 1.54–1.43 (m, 2H). 13C NMR (75 MHz, DMSO) δ 164.7,
163.1, 159.5, 156.8, 154.6, 150.1, 134.3, 133.2, 130.0, 128.8, 122.9,
119.2, 117.7, 115.3, 110.6, 108.6, 105.2, 56.4, 56.3, 26.8, 24.4, 21.0.
SwissADME1 was used for drawing, chemical structure
property prediction, and calculations (Daina et al., 2017).
1http://www.swissadme.ch/
BV-2 Microglia Culture
The murine microglial cell line BV-2 was from Banca Biologica
e Cell Factory (Genova, Italy). Cells were cultivated and
maintained in RPMI1640 medium supplemented with 10%
FCS, 100 U/ml penicillin, 100 mg/ml streptomycin, and 5 ml
L-glutamine (200 mM) at 37◦C in a humidified incubator under
5% CO2 and 95% air. When cells reached confluency, they were
split into new flasks or they were plated accordingly for the
experiments as described previously (Plastira et al., 2016).
CATH.a Neurons Culture
The murine neuronal cell line CATH.a was from ATCC.
Cells were grown and maintained in RPMI1640 medium
supplemented with 10% horse serum, 5% FCS, 1% penicillin-
streptomycin, 0.4% HEPES, and 0.2% sodium pyruvate at 37◦C
(5% CO2). When cells reached confluency, they were split into
new flasks (subcultivation ratio of 1:4) using 0.12% trypsin
without EDTA as described (Waltl et al., 2013).
LPA Treatment
Cells were plated in 6 or 12-well plates and allowed to adhere for
2 days. Cells were always kept in serum-free medium overnight
before incubation with LPA and LPA plus each inhibitor.
Aqueous LPA stock solutions (5 mM) were stored at −70 ◦C.
Only freshly thawed stocks were used for the experiments.
Inhibitor Treatments
AS2717638 and compound 3 were diluted in DMSO (stock
concentration: 10 mM) and kept at −20◦C. During the
experiments, AS2717638 and compound 3 were used at a final
concentration of 0.1 µM and 1 µM, respectively. The highest
DMSO concentration was 0.01% (v/v) and used as vehicle control
throughout the study.
MTT Assay
The toxicity of the two inhibitors on BV-2 cells was assessed using
the MTT assay. Cells were plated in 24-well plates and grown
to confluency. The cells were incubated with MTT (1.2 mM;
in serum-free medium) for 1 h, washed with PBS and cell lysis
was performed with isopropanol/1 M HCl (25:1 v/v) on a rotary
shaker at 1,200 rpm for 10 min. Finally the samples were diluted
1:5 and absorbance was measured at 570/650 nm on a Victor
1,420 multilabel counter (Wallac).
Immunoblotting
After treatment with the experimental substances for the
indicated time periods, BV-2 cells were washed twice with
ice-cold PBS and lysed in RIPA buffer (50 mM Tris-HCl
pH 7.4, 1% NP-40, 150 mM NaCl, 1 mM Na3VO4, 1 mM
NaF, 1 mM EDTA) containing protease inhibitors (Sigma;
aprotinin, leupeptin, pepstatin: 1 µg/ml each), 10 µM PMSF and
phosphatase inhibitors cocktail (Thermo Scientific, Waltham,
MA, USA). Protein content was determined using the BCA
kit (Thermo Scientific) and BSA as standard. Protein samples
(100 µg) were separated on 10% SDS-PAGE gels and transferred
to polyvinylidene difluoride membranes. Membranes were
blocked with 5% low-fat milk in Tris-buffered saline containing
Tween 20 (TBST) for 2 h at RT and incubated with the primary
Frontiers in Cellular Neuroscience | www.frontiersin.org 3 November 2019 | Volume 13 | Article 531
Plastira et al. LPAR5 Antagonism Attenuates Microglial Inflammation
antibodies overnight with gentle shaking at 4◦C. After the
removal of primary antibodies, the membranes were washed for
30 min in TBST and incubated for 2 h at RT with anti-rabbit
(1:10,000) or anti-mouse (1:5,000) as secondary antibodies.
Following three washes with TBST for 1 h, immunoreactive
bands were visualized using ECL or ECL plus reagents and
detected with a chemiluminescence detection system (ChemiDoc
Bio-Rad, Berkeley, CA, USA). In some cases, the membranes
were stripped using a stripping buffer (140µl β-mercaptoethanol
in 20 ml buffer 60 mM Tris/ 2% SDS, pH 6.8) under gentle
shaking for 30 min at 50◦C in a water bath, washed for 1 h in
TBST, blocked with 5% low-fat milk in TBST for 1 h at room
temperature and probed with the pan antibodies for p65-NF-
kB, c-Jun, STAT1, and STAT3 as described (Plastira et al., 2017).
Anti-β-actin (1:5,000) was used as loading controls.
Flow Cytometry
Flow cytometry was used to quantitate the percentage of CD40,
CD86, andCD206 positivemicroglia cells. BV-2 cells were seeded
in triplicate onto 6-well at a density of 1 × 105 cells per well.
After 24 h serum-starvation, cells were incubated with vehicle
control, LPA or LPA plus the antagonists for 12 and 24 h. Cells
were then collected, blocked using the Ultra V blocker (Thermo
Scientific) and incubated with PE anti-CD40, APC anti-CD86,
or PE anti-CD206 antibody (1:50). After fixation, samples were
measured using a Guava easyCyte 8 Millipore flow cytometer.
ELISA
IL-1β, TNFα, IL-6, CCL5 (RANTES), CXCL2 (MIP-2), and
CXCL10 (IP-10) concentrations in the cellular supernatants
were quantitated using the murine ELISA development kits
(Peprotech, NJ, USA; Plastira et al., 2016). Briefly, BV-2 cells
were seeded in triplicate onto 12-well plates at a density of
5 × 104 cells per well, serum-starved (o/n), and incubated in
serum-free medium, containing LPA in the absence or presence
of the antagonists for the indicated time periods. For each time
point, the supernatants were collected and kept at −70◦C until
further use. The concentrations of the cytokines and chemokines
were determined using the external standard curve.
LDH Assay
Lactate dehydrogenase is a soluble enzyme located in the cytosol
and released into the culture medium upon cell lysis or damage.
LDH activity can, therefore, be used as an indicator of membrane
integrity and thus a measurement of cytotoxicity (Cayman
Chemical, Ann Arbor, MI, USA). The assay was performed
as previously described (Plastira et al., 2016). In brief, BV-2
cells were seeded in triplicate into 6-well plates at a density of
1 × 105 cells per well, serum-starved overnight and incubated in
serum-free medium, containing LPA in the absence or presence
of the antagonists for the indicated time periods. For each time
point, the supernatants were collected and kept at −70◦C until
further use.
CATH.a neurons were seeded in a 96-well plate at a
concentration of 1 × 105 cells per well, and following overnight
serum-starvation, the cells were incubated in the presence of
the above-mentioned supernatants. Three wells containing only
medium without cells were used for background control. In
order to measure maximum and spontaneous release, cells were
incubated with 10% Triton X-100 and assay buffer, respectively.
After 24 h, the plate was centrifuged at 1,300 rpm for 5 min.
One-hundred microliter of the supernatants was transferred to
a new 96-well plate and 100 µl of LDH reaction solution was
added to each well. The plate was incubated at 37◦C for 30 min
and the absorbance at 490 nm was measured using a plate reader
(Plastira et al., 2017).
Statistical Analysis
All experiments were performed using three replicates per
experimental group and repeated three times (unless otherwise
stated). Statistical analyses were performed using the GraphPad
Prism version 6 for Mac (GraphPad Software, Inc., San Diego,
CA, USA). Data obtained from independent measurements were
analyzed by one-way ANOVA followed by Bonferroni’s post hoc
test and presented as mean± SD.
RESULTS
AS2717638 and Compound 3 Inhibit
LPA-Mediated Pro-inflammatory
Transcription Factor Phosphorylation
Structures and physicochemical properties of AS2717638 and
compound 3 are displayed in Figures 1A,C. As a first step in our
study, we analyzed whether the two LPAR5 antagonists exhibit
toxic effects in BV-2 microglia cells. Incubation with increasing
concentrations of AS2717638 (0.1–10 µM) revealed that BV-2
cell viability was reduced between 10% and 30% after a 2 h
incubation at concentrations ≥0.5 µM (Figure 1B). Therefore
AS2717638 was used at 0.1 µM in all experiments. After a
24 h incubation, cell viability was decreased by 55 and 70%
(1 and 10 µM, respectively; Figure 1B). In contrast, compound
3 reduced viability by 50 (2 h) and 60 (24 h) % only at
the highest concentration (10 µM) used (Figure 1D). In the
experiments described below, compound 3 was used at 1 µM,
a concentration without detrimental effects on cell viability. At
these concentrations, both inhibitors attenuated LPA-mediated
morphological changes (cell perimeter and cellular surface area)
of BV-2 cells (Supplementary Figure S1).
During previous experiments, we examined the effect of
LPA on microglial inflammatory response and reported that
LPAR5 controls the LPA induced pro-inflammatory phenotype
in microglia cells (Plastira et al., 2017). In order to test the impact
of AS2717638 and compound 3 on activation/phosphorylation
of transcription factors in BV-2 cells in response to LPA
(1 µM) treatment, we used immunoblot analysis. Cells were
incubated in the presence or absence of each inhibitor for
different time periods and the activation of transcription
factors was analyzed. Results of these experiments indicated
that both LPAR5 antagonists clearly suppressed LPA-induced
phosphorylation of p65-NF-kB, c-Jun, STAT1, and STAT3
(Figure 2). AS2717638 used at 0.1 µM attenuated STAT1 and
STAT3 phosphorylation back to or below baseline at the
8 h time point, and comparable results were obtained for
pp65 and pcJun (Figure 2A). Also compound 3 (1µM) decreased
phosphorylation of all transcription factors at one or more time
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FIGURE 1 | Structure, physicochemical properties and cytotoxic potential of AS2717638 and compound 3. Chemical structures of AS2717638 (A) and compound
3 (C). SwissADME was used to calculate physicochemical properties relevant to the “rule of five” that predict drug-likeliness of a compound (Lipinski et al., 2001).
Cytotoxicity was assessed using the MTT assay. BV-2 microglia cells were cultured in 6-well plates, serum-starved overnight (o/n) and incubated with the indicated
concentrations of AS2717638 (B) and compound 3 (D) in DMSO for 2 and 24 h. DMSO was used as vehicle control. For convenience, the names of the inhibitors
are presented as AS and comp3. Results from three independent experiments in triplicates are presented as mean ± SD (##p < 0.01, ###p < 0.001 compared to
vehicle control; one-way ANOVA with Bonferroni correction).
points (Figure 2B). The bar graphs represent densitometric
analysis from three independent experiments.
AS2717638 and Compound 3 Attenuate
LPA-Induced Cyto-/Chemokine Secretion
by BV-2 Microglia
We then quantitated the concentrations of secreted IL-6,
TNFα, IL-1β, CXCL10, CXCL2, and CCL5 using ELISA kits
(Figure 3). These experiments revealed that both, AS2717638 and
compound 3 decreased secretion of IL-6, TNFα, IL-1β,
CXCL10, CXCL2, and CCL5 almost back to base-line levels.
For AS2717683 the decrease in CXCL2 concentrations was
statistically not significant.
LPA-Induced Pro-inflammatory Marker
Expression Is Attenuated by
AS2717638 and Compound 3
In the next set of experiments, we analyzed the impact
of LPAR5 antagonism on the expression of pro- and
anti-inflammatory markers using Western blotting and flow
cytometry. Immunoblotting experiments revealed that treatment
with AS2717638 (Figure 4A) or compound 3 (Figure 4C)
significantly reduced LPA-dependent COX-2 expression yet
only AS2717638 could increase the expression of Arg-1, a
marker protein for the M2 microglia/macrophage phenotype.
Densitometric evaluation of immunoreactive bands from three
separate experiments is given in the bar graphs (Figures 4B,D).
Using flow cytometry, we then analyzed the expression pattern
of specific polarization surface markers in LPA-stimulated BV-2
cells in the absence or presence of the antagonists. As shown
in Figures 4E,F, both antagonists abrogated LPA-mediated
CD40 and CD86 (except AS2717638 at 24 h) upregulation,
whereas CD206 levels were only upregulated by AS2717638
(Figure 4G). Scatterplots representative of these analyses are
shown in Supplementary Figure S2.
AS2717638, but Not Compound 3, Reduces
Neurotoxic Properties of Conditioned
Medium Collected From LPA-Stimulated
BV-2 Cells
CATH.a neurons were incubated with the supernatants collected
from LPA-treated (in the absence or presence of AS2717638 or
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FIGURE 2 | AS2717638 and compound 3 attenuate lysophosphatidic acid (LPA)-induced phosphorylation of pro-inflammatory transcription factors. BV-2 microglia
cells were cultured in 6-well plates and serum-starved o/n. Cells were treated with DMSO, DMSO plus LPA (1 µM), and LPA (1 µM) in the presence of (A)
AS2717638 (0.1 µM) or (B) compound 3 (1 µM) for the indicated time periods and cell protein lysates were collected. The phosphorylation states along with the total
levels of STAT1, STAT3, p65-NF-kB, and c-Jun were detected using Western blotting. If two bands appeared for one protein [e.g., (p)STAT3] both bands were
included in the densitometric evaluation. Protein/loading control ratios were normalized to the ratio of unstimulated microglia (mean value of DMSO controls was set
to 1). One representative blot out of three separate experiments and the densitometric analysis of each protein expression from three independent experiments is
presented (∗∗p < 0.01; ∗∗∗p < 0.001 compared to DMSO-treated cells; #p < 0.05; ##p < 0.01; ###p < 0.001 each inhibitor compared to LPA-treated cells; one-way
ANOVA with Bonferroni correction).
compound 3) BV-2 cells. Neuronal cell death was quantified
using an LDH activity kit (Plastira et al., 2017). BV-2 medium
collected from LPA-stimulated cells induced a 2.5-fold increase
in LDH activity in CATH.a cultures (Figure 4H, gray bars).
In contrast, medium collected from LPA-activated microglia
that were cultured in the presence of AS2717638 did not affect
neuronal viability (red bars). Although compound 3 showed a
tendency to decrease cytotoxic effects of microglia-conditioned
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FIGURE 3 | AS2717638 and compound 3 reduce LPA-mediated secretion of pro-inflammatory cytokines and chemokines. BV-2 microglia were cultured on 24-well
plates and serum-starved o/n. The supernatants were collected after incubation with vehicle control (DMSO), DMSO plus LPA (1 µM) or LPA plus AS2717638 (0.1
µM) or compound 3 (1 µM) for 2, 8, and 24 h. ELISA was used to quantify the concentrations of IL-6, TNFα, IL-1β, CXCL10 (IP-10), CXCL2 (MIP-2), and CCL5
(RANTES). Results shown represent mean ± SD from three independent experiments performed in triplicate (∗p < 0.05; ∗∗p < 0.01 compared to vehicle control;
#p < 0.05, ##p < 0.01; each inhibitor compared to LPA-treated cells; one-way ANOVA with Bonferroni correction). No bars = below detection limit.
medium these effects were statistically not significant (Figure 4H,
green bars).
DISCUSSION
Depending on the disease context, extrinsic signals determine
whether microglia acquire a beneficial or detrimental phenotype.
Their critical role in CNS homeostasis makes these cells potential
therapeutic targets, which necessitate a thorough understanding
of different phenotypic subclasses, transcriptome profiles, and
pathways that modulate their function.
In numerous pathological conditions, such as (neuro-)
inflammation, brain injury, neuropathic pain and gliomas,
LPA levels can increase and through downstream signaling
counteract brain function. Aberrant ATX-LPA signaling has
been implicated in several neurological disorders including
neuropathic pain and schizophrenia (Yang et al., 2015). LPA
levels were elevated in a controlled cortical impact mouse
model of TBI (Crack et al., 2014; Eisenried et al., 2017), in
Huntington’s disease mouse brains (Vodicka et al., 2015) and
in glioblastoma multiforme (Tabuchi, 2015). Tissue distribution
analyses revealed that ATX gene expression is induced in human
AD frontal cortex and the TauP301L mouse model (Umemura
et al., 2006). Altered expression levels and activity of ATX with
accompanying alterations in LPA signaling have recently been
implicated in the pathogenesis of AD (Ramesh et al., 2018).
Due to its importance in numerous diseases, ATX makes
an attractive target for therapeutic intervention (Matralis et al.,
2019). However, there may be therapeutic benefit by selectively
targeting one or more LPA receptor subtypes (Herr et al.,
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FIGURE 4 | AS2717638 and compound 3 restore a neuroprotective microglial phenotype while only AS2717638 reduces neurotoxicity of microglia-conditioned
medium. Serum-starved microglia cells were treated with DMSO, DMSO plus LPA (1 µM), and LPA plus AS2717638 (0.1 µM; A) or compound3 (1 µM; C) for 2, 8,
and 24 h. Cell lysates were collected and the expression of COX-2 and Arg-1 was monitored by immunoblotting. One representative plot for each protein and the
densitometric analysis (B,D; mean ± SD) from three independent experiments are presented (mean value of DMSO controls was set to 1). In a parallel experiment,
serum-starved (o/n) BV-2 cells were cultivated in the presence of DMSO, DMSO plus LPA (1 µM) or LPA in the presence of AS2717638 (0.1 µM) or compound 3 (1
µM) for the indicated times. Cells were stained with PE-conjugated anti-CD40 (E), APC-conjugated anti-CD86 (F) or PE-conjugated anti-CD206 (G) antibodies and
analyzed using a Guava easyCyte 8 Millipore flow cytometer. Results are shown as mean values ± SD. (H) CATH.a neurons were incubated for 24 h with conditioned
media collected from LPA-treated BV-2 cells in the presence or absence of AS2717638 (0.1 µM) or compound 3 (1 µM) for 12 and 24 h. The LDH levels were
detected and cytotoxicity was calculated according to the manufacturer’s instructions (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001 compared to DMSO-treated cells;
#p < 0.05; ##p < 0.01; ###p < 0.001 each inhibitor compared to LPA-treated cells; one-way ANOVA with Bonferroni correction).
2018). Unfortunately, up to date, only a few selective antagonists
for LPAR5 have been reported (Kozian et al., 2012, 2016;
Murai et al., 2017). In a previous study, using one of those
specific LPAR5 inhibitors (TCLPA5), we unraveled that the
LPA/LPAR5 axis controls the inflammatory and migratory
response in microglia cells (Plastira et al., 2016). In the present
study, we analyzed the potency of two newly developed small
molecule LPAR5 antagonists (AS2717638 and compound 3)
to interfere with this LPA-induced pro-inflammatory response.
AS2717638 was successfully used in preclinical rodent models
of neuropathic pain where the inhibitor showed high potency,
selectivity, and CNS penetration with broad analgesic effects
(Murai et al., 2017). Compound 3 is a diphenylpyrazole
compound that was identified during a compound library
screening approach (Kozian et al., 2016). Compound 3 is
metabolically stable, has good absorption properties, and is
bioavailable after oral administration in mice (Kozian et al.,
2016). In vitro, compound 3 inhibits LPA-mediated activation
(MCP-1 expression) of human mast cells or BV-2 microglia.
However, and in contrast to AS2717638, compound 3 displays
physicochemical properties that are predicted to have (according
to Lipinski’s ‘‘rule of five’’; Lipinski et al., 2001) poor oral
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absorption and/or distribution properties: the molecular weight
is>500, logP is>5, and there are eight hydrogen-bond acceptors
present in the compound (Figure 1C). On the other hand the
polar surface area is <140 Å2, which could compensate the high
molecular weight (Veber et al., 2002) and mediate the good oral
bioavailability observed in C57BL/6 mice (Kozian et al., 2016).
A first important observation from our in vitro study is that
AS2717638 can regulate the BV-2 response to LPA at a 10-fold
lower concentration compared to compound 3 (0.1 µM vs.
1 µM). Although both compounds have the potential to decrease
cell viability, the concentrations inducing detrimental effects
were far higher than the reported IC50 values. These findings
indicate an appropriate (in vitro) effect-to-toxicity window that is
devoid of unspecific cellular responses. The inhibitory effects of
the two LPAR5 antagonists were first assessed by analyzing their
impact on the LPA-induced expression of different transcription
factors. c-Jun is a component of AP-1 transcription factors and
regulates the expression of many inflammatory and cytokine
genes, which are involved in brain inflammation (Raivich, 2008).
In addition, constitutive and inducible activation NF-kB in glial
cells regulates inflammatory processes that exacerbate various
diseases (Kaltschmidt and Kaltschmidt, 2009). Specifically in
microglia, NF-kB regulated activation induced the release of
pro-inflammatory cytokines and caused neurotoxicity (Block
et al., 2007; Khasnavis et al., 2012; Yao et al., 2013; Frakes et al.,
2014; Parisi et al., 2016). AS2717638 and compound 3 effectively
inhibited phosphorylation of both c-Jun and p65 in LPA treated
BV-2 cells at 8 and/or 24 h post-inhibitor addition indicating
long-term regulation (Figures 2A,B). However, it should be
noted that BV-2 cells used during the present study exhibit
less pronounced induction of pro-inflammatory genes and lower
cytokine secretion in response to LPS when compared to primary
microglia (He et al., 2018), facts indicating potential limitations
for the use of the BV-2 model.
In the CNS, STAT proteins are associated with development,
hormone release, tumorigenesis, and inflammation (Nicolas
et al., 2013). STATs are mediators of immunity and play
important roles in inflammatory disease (O’Shea and Plenge,
2012). In brain tumors, STAT3 is highly upregulated (Gu
et al., 2008; Chen et al., 2010). The role of STAT3 in brain
inflammation is not entirely clear since both anti-inflammatory
and pro-inflammatory mediators can activate it. In microglia,
it was reported that the JAK2-STAT3 pathway induces
pro-inflammatory responses (Huang et al., 2008; Yang
et al., 2010). In contrast, the role of STAT1 is more
clear-cut and usually promotes inflammation, expression
of different cytokines, and production of NO and ROS
(Delgado, 2003; Rezai-Zadeh et al., 2008; Herrera-Molina
et al., 2012; Rauch et al., 2013). Different expression levels
have been detected in glial cells (De-Fraja et al., 1998) and
are associated with CNS pathological conditions such as
brain inflammation (Hashioka et al., 2009), traumatic brain
injury (Okada et al., 2006), and cerebral ischemia (Choi et al.,
2005; Satriotomo et al., 2006). Both antagonists significantly
decreased the activation of STAT3. Differences have been
observed during STAT1 phosphorylation. Even though both,
AS2717638 and compound 3 abrogated STAT1 activation
at 8 h, AS2717638 lost its inhibitory potential at the
24 h time point.
Microglia activation is accompanied by directed migration
to the site of injury and subsequent release of cytokines,
chemokines, NO, or ROS, which can have beneficial or
detrimental effects on bystander cells (Ransohoff and Perry,
2009). The time-dependent expression profiles of cyto-
/chemokines are specific for a pro- or anti-inflammatory
microglia phenotype (Chhor et al., 2013). In response to LPA,
an upregulated expression of IL-6, TNFα, IL-1β, CXCL10,
CXCL2, and CCL5 was observed, in line with reports for
LPS-activated primary murine microglia (Chhor et al., 2013).
In addition, IL-1β, IL-6, TNFα, and the chemokines CCL5,
and CXCL2 are implicated as regulators of the inflammatory
response in (animal) models of TBI (Gyoneva and Ransohoff,
2015) where LPA concentrations are elevated (Crack et al.,
2014). AS2717638 and compound 3 significantly decreased
LPA-induced expression of those cytokines and chemokines, at
least at one time point. Differences were observed for CXCL2,
where AS2717638 had no statistically significant inhibitory
effect. Both inhibitors abrogated the expression of COX2,
CD40 and CD86 (pro-inflammatory markers). This is in line
with earlier findings where we could demonstrate that TCLPA5
(an LPAR5 inhibitor) attenuates ERK1/2 and JNK activation,
which both couple to COX-2 expression (Plastira et al., 2017).
We can currently not offer an explanation for Arg1 upregulation
in response to LPA (Figure 4D). In contrast to compound 3
only AS2717638 upregulated the anti-inflammatory markers
Arg1 and CD206 (Figures 4B,G).
Microglia-induced neurotoxicity (Biber et al., 2014) is
mediated by the constant production of pro-inflammatory
cytokines and chemokines, NO (Liu et al., 2002), and ROS
(Hsieh and Yang, 2013). An increase in oxidative stress
might have detrimental effects (e.g., cell membrane damage,
oxidative modification of lipids, covalent modification of
intracellular proteins, or reduced antioxidant capacity of
neurons) thereby promoting disease progression (Valko et al.,
2007; Hsieh and Yang, 2013). During the present study, we
found that supernatants collected from LPA plus AS2717638-
treated BV-2 cells ameliorated cytotoxicity towards CATH.a
neurons. Although compound 3 treatment showed a tendency
for decreased neurotoxicity these effects were statistically
not significant.
In conclusion, both LPAR5 antagonists are promising
candidates to pharmacologically modulate the pro-inflammatory
LPA/LPAR5 axis in microglia since AS2717638 and compound
3 abrogated phosphorylation of pro-inflammatory transcription
factors and reduced secretion of inflammatory cytokines and
chemokines. Our results point towards the possibility that
LPAR5 antagonists might be useful pharmacological compounds
to dampen the neuro-inflammatory response ofmicroglia in CNS
diseases that associate with aberrant LPA production.
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